Innovative Contracting Webinar - Insights & Trends: September 2023 USA/LATAM Session

 

The on-demand edition of the latest in Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting.

Omar Ali and Adam Meads discuss current perceptions of payment-over-time models when thinking about alternative financing for Gene Therapies, collected directly from US payer interviews (National Plan, Regional Plan, IDN, Employer Coalition Organization) conducted by Verpora in 2023. They explore what these payers are saying about warranty schemes, explore a case study of Roctavian for Severe Hemophilia A, and the current perceptions of barriers for IC and the future of IC in the U.S.

Plus, an update on the Value Based Healthcare landscape in Brazil, and an overview of Innovative Contracting, its benefits and challenges, and importance to the industry.


Disclaimer: This presentation is for discussion purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this webinar may be reproduced for commercial purposes without the express permission of Verpora.

 

Speakers

Omar Ali
Head of Payers, Verpora
LinkedIn

Adam Meads
Head of Research & Analytics, Verpora
LinkedIn

Harry Osborn
Account Director, Verpora
LinkedIn

Previous
Previous

Spain: Is this the end for IPT plans?

Next
Next

Innovative Contracting Insights & Trends April 2023 USA/LATAM